Background; Monoclonal antibodies are being utilized for treatment of patients with low-grade non-Hodgkin's lymphoma as well as other cancers. Results from phase I and II clinical studies has shown that the chimeric monoclonal antibody Rituximab has minimal toxicity and significant therapeutic activity in low grade non-Hodgkin's lymphoma.
Introduction
Over the last two decades, the therapeutic anti-tumor potential of monoclonal antibodies has been extensively evaluated. Monoclonal antibodies held the promise of being more specific than current chemotherapeutic approaches and of killing cells by novel cytotoxic mechanisms that might be effective against chemoresistant tumor cells.
The initial results from a number of phase I single institution clinical trials however, were for the most part, disappointing (for review see [1] ). The effectiveness of monoclonal antibody therapy was limited by a number of factors including: tumor cell heterogeneity, antigenic cross-reactivity, antigenic modulation, shedding or secretion of the targeted tumor antigen, ineffective tumor penetration, short circulating half-life of the monoclonal antibody, immunogenicity of the monoclonal antibody, and ineffective activation of the host immune system.
Because low-grade non-Hodgkin's lymphoma is currently an incurable lymphoproliferative disorder, monoclonal antibodies have been extensively evaluated as anti-cancer reagents in this disease. Promising results were reported in a series of phase I-II clinical studies using monoclonal anti-idiotype antibodies but practical difficulties related to the custom synthesis of these reagents and the emergence of idiotypic variants have reduced the feasibility of this approach [2] [3] [4] . Although CAMPATH 1H, directed at CDw52 expressed on both B and T lymphocytes, was therapeutically active, the profound immunosuppression associated with the rapid and persistent depletion of B and T lymphocytes makes this antibody unsatisfactory for use as an anti-tumor reagent [5] . Monoclonal antibodies directed against CD19 expressed on B lymphocytes have induced transient partial responses in a small number of patients and approaches to enhance this therapeutic activity by conjugating toxins to the antibody are underway [6] . Press et al. reported promising and seemingly more durable results in a small number of patients with the 1F5 monoclonal antibody directed at the CD20 antigen expressed on B lymphocytes [7] . Striking results were obtained by three groups using radiolabelled conjugates of antibodies directed at CD20 with complete response rates of greater than 70% in highly pretreated patients with recurrent low-grade lymphoma [8] [9] [10] [11] [12] [13] .
This report describes a mouse/human chimeric monoclonal antibody against the CD20 antigen [14] . The rationale for its development was to further enhance the therapeutic activity of the parent murine monoclonal antibody by potentially reducing its immunogenicity, increasing its circulating half-life, and improving its cytotoxicity [15] [16] [17] . This antibody is relatively non-toxic and has therapeutic activity against B-cell lymphoma [18] . Recently the results of a large multicentre pivotal trial involving 166 patients with recurrent low-grade lymphoma have been reported [19] . Objective responses were seen in 50% of evaluable patients. Interestingly, only one of 166 patients developed a human antichimeric (HACA) antibody response.
We describe the results of a detailed pharmacokinetic analysis that was performed in this study. We show that the half-life of this monoclonal antibody was indeed greater than the half-lives of other murine monoclonal antibodies described in the literature, and, more importantly, that a statistically significant correlation was found between the median serum antibody concentration and clinical response.
Patients and methods

Rituximab anti-CD20 monoclonal antibody
The chimeric monoclonal antibody Rituximab has human IgGl/k constant regions with mouse variable regions taken from the murine anti-CD20 monoclonal antibody IDEC-2B8. It was genetically engineered, produced, and provided by IDEC Pharmaceuticals (San Diego, CA) under an Investigational New Drug application [14] .
Phase III multi-centre trial
The pivotal multi-centre clinical trial has been described in detail elsewhere [20] . Briefly, patients with recurrent (up to four relapses) or refractory low-grade non-Hodgkin's lymphoma (IWF A, B, C or D) with measurable progressive disease and normal renal and hematologic function, and with a life expectancy of at least three months, were eligible. Additionally, patients having a total lymphocyte count >5,000/mm 3 or single lesions measuring > 10 cm in diameter were excluded. Detailed written informed consent consistent with the requirements of the Institutional Review Board of the participating institutions were obtained from all patients. A lymph node biopsy was obtained on all patients within six months of treatment. Biopsy was repeated if there was intervening therapy since the last biopsy. Patients previously treated with a murine monoclonal antibody were required to have no evidence of a human anti-mouse antibody (HAMA) response at study entry.
Patients received infusions of Rituximab at 375 mg/m 2 once weekly for four doses over a period of 22 days. Optional premedications included acetaminophen and/or diphenhydramine. Toxicity was documented using the National Cancer Institute's Common Toxicity criteria. Response was documented using history and physical exam as well as bidimensional radiologic measurements at one month post completion of the therapy. Studies were then performed every three months during the first two years and then at six month intervals until the time of progression. Bilateral bone marrow aspirations and biopsies were performed at initial work-up and upon confirmation of response. Response categories included: complete response (CR)-complete resolution of all measurable (all nodes less than 1 cm x 1 cm) and non-measurable disease including normalization of previously abnormal bone marrow biopsies, and partial response (PR)-at least 50% reduction in tumor size of measurable lesions and no simultaneous increase in size of any other lesion or no new lesions. Prior to being confirmed, PR and CR classifications were reassessed 28 days following the original observations of response [21] .
Pharmacokinetic measurements
Serum samples for Rituximab were obtained prior to and immediately after each infusion at weeks 1, 2, 3, and 4 and at one week, one month, and three months post-treatment. In a random subset of 14 patients, additional serum samples were obtained at 24, 48, 72, 96 hours after the first and fourth infusions. Samples were stored at -20 C until analysis.
Serum levels of Rituximab were performed by enzyme linked immunosorbent assay (ELISA). Microwell plates were coated with a purified goat anti-Rituximab idiotype polyclonal antiserum. Serial dilutions of patient serum were added to the wells and a goat anti-human IgG conjugated to horseradish peroxidase was used for detection. The plates were developed using the substrate 2,2-azinobis(3-ethylbenzthiazoline sulfonic acid) (ABTS) and quantitated using absorbence spectophotometry with a known standard curve of Rituximab. This assay was validated to quantify ^0 5 ug/ml of Rituximab in serum.
The trapezoidal area-under-the curve (AUC) and clearance were calculated by noncompartmental methods. Clearance for the first infusion was determined using; Cl = Dose/AUC (0-infinity) where AUC (0-infinity) = AUC (0-168 hours) + Cp (168 hours/beta and beta = ln(2)/T )/2 . Clearance for the fourth infusion was determined using: CI = Dose/AUC (0-n) where n is the dosing interval (168 hours). C max and C m i n were reported as the observed value. The T 1/2 was derived from Rituximab serum level data analyzed using a one-or twocompartment intravenous infusion model by PCNONLIN software version 4.
Statistical considerations
The Kaplan-Meier method was used to analyze the time to progression and duration of response. The Wilcoxon ranksum test was used for the comparison of serum concentration data by clinical response.
Results
Serum concentration of Rituximab increased with each infusion
The serum concentration of Rituximab was quantitated by ELISA before and after each antibody infusion and at one week, one and three months post-treatment. Table 1 shows the mean and median values of the pre Table I . Serum concentration by visit schedule. All patients (n = 166). time points. At all time points the post infusion level was higher than the pre infusion level, increase in the pre and all timp n n i n t s Hnrina
In addition there was a steady post infusion antibody levels at trpatmpnr with a rnnrinnpH HP- cline during the post-treatment time points. Low levels of Rituximab could still be detected in 104 and 13 patients at three and six months post treatment, respectively ( Table 1 ). The median Rituximab serum levels were 20.3 ug/ml (range 0.0-96.8 ug/ml in 104 patients) at three months post-treatment and 1.3 ug/ml (range 0.0-28.7 ug/ml in 13 patients) at six months post-treatment.
Rituximab levels correlate with patient response
An analysis was performed to determine whether the levels of Rituximab correlated with patient response. Table 2 shows that at all time points the median serum level of Rituximab was higher in the responders than in the nonresponders. These differences reached statistical significance by the second infusion for pre-infusion levels and by the fourth infusion for post infusion levels. The levels of Rituximab were statistically significantly higher for the responders at all three post-treatment time points. At three months post-treatment, median serum levels in 62 responders were 25.4 ug/ml compared with 5.9 ug/ml in 42 nonresponders.
Other clinical correlations with Rituximab levels
A number of analyses were performed to determine whether serum Rituximab levels correlated with other clinical parameters. A linear regression analysis revealed that there was an inverse correlation between the absolute level of circulating peripheral blood B cells at baseline and antibody concentration (Table 3 ). This correlation was statistically significant at all time points except immediately after the first infusion and at three months post-treatment. 1 Statistically significant at the 0.05 level. Slope statistically significant at the P < 0.05 level.
The serum Rituximab level also correlated inversely with two different measurements of tumor bulk at baseline -the maximum diameter of the largest lesion as well as the sum of the product of the perpendicular diameters (SPD) of the six largest lesions (Table 4) . These measurements were statistically significant at all time points except immediately after the first infusion.
Finally, an univariate analysis showed that the serum Rituximab level correlated with the histologic subtype of the patient. Rituximab levels were significantly lower for those patients with International Working Formulation (IWF) Histologic Type A as compared to those with IWF types B, C or D. These associations were found to be statistically significant immediately prior to the fourth Rituximab infusion and at all three post-treatment time points (Table 5) .
The T1/2 of Rituximab increased during the treatment course
Traditional pharmacologic assessments of the area under the curve (AUC) and T 1/2 were obtained on a random subset of the patients treated in this clinical trial. Fourteen patients had additional serum samples drawn at 24, 48, 72, and 96 hours after the first and fourth infusions. The serum antibody concentrations at these time points were used to calculate the antibody half-life (T 1/2 ) and clearance for the first and fourth infusion. The results of this analysis are shown in Table 6 . The T 1/2 increased from 76.3 hours to 205.8 hours from the first to the fourth infusions. The antibody clearance during the treatment course decreased nearly four fold from 38.2 ml/hour to 9.2 ml/hour. A univariate analysis did not reveal any correlation between other pharmacokinetic parameters such as T^ or antibody clearance and response.
Discussion
We have previously shown that the chimeric monoclonal antibody Rituximab is therapeutically active in patients with low-grade non-Hodgkin's lymphoma [18] . In two previous phase I-II dose escalation studies, 62 patients were treated with varying doses and schedules of Rituximab. In the initial single dose study, two of 15 patients experienced partial responses whereas 17 of 37 patients receiving multiple doses of Rituximab responded including three complete responders [20] . In the study reported here, utilizing the highest dose of antibody administered in the previous multiple dose study, 10 CRs and 70 PRs occurred in 166 patients. The median duration of response and time to progression are 11.6 and 13.2 months, respectively [19] . In these 166 patients we found a statistically significant correlation between Rituximab concentration and response. This observation was strengthened by the finding that the correlation was found at multiple time points. Interestingly in the two previous phase I-II studies of Rituximab, there was a statistically significant correlation between the amount of antibody infused and serum levels. Others have also demonstrated a correlation between antibody dose and serum level [2, 7] . The level of Rituximab used in this study (375 mg/m 2 ) was chosen based upon these previous studies because it was a safe, non toxic dose with demonstrable therapeutic activity. However extrapolation of these results suggests that higher doses of Rituximab may result in even higher serum levels of Rituximab and possibly greater therapeutic activity in certain patient subsets.
Others have also found a correlation between the serum concentration of a therapeutic monoclonal antibody and clinical response. Meeker et al. and Brown et al. found that anti-tumor responses occurred in patients in which free antibody accumulated during treatment with anti-idiotype antibodies in patients with recurrent follicular lymphoma [2, 3] . Similarly, Press et al. observed that, of four patients treated with monoclonal antibody 1F5 directed against CD20, the best response occurred in the patient who achieved the highest serum level of antibody [7] .
The serum level of a therapeutic agent such as a monoclonal antibody is related to the infusion dose and the clearance orT 1/2 which is partly dependent upon the amount of antigen present. The serum levels measured only reflect free antibody, not bound antibody; there is not a reliable and practical method to detect bound antibody. In the study described here, relatively large doses of monoclonal antibody were infused (375 mg/m 2 ). Press et al. used escalating doses from 5 mg/m 2 to 800 mg/m 2 per infusion with total doses ranging from 52.4 mg to 2380 mg for treatment with monoclonal antibody IF5 [7] . In the studies using CAMPATH 1H, 25-30 mg were infused per treatment with total doses ranging from 314 mg to 1090 mg [5, 22] . In studies using monoclonal anti-idiotype antibodies, doses of antibody sufficient to overcome circulating idiotype were administered with single doses as high as 900 mg and total doses ranging from 400 to 3183 mg [2] .
In the study reported here, patients were given four doses of 375 mg/m 2 ; thus, the mean total dose received was 2858 mg (range 1335-4000 mg). This dose is comparable to the highest total dose of antibody ever given with anti-idiotype antibody treatment and is much greater than the total doses given with 1F5 and CAM-PATH 1H. Optimized expression systems and manufacturing systems that produce large quantities of antibody make it possible to dose patients with such large amounts [14] . The high doses of Rituximab given saturate antigenic sites, as shown by the accumulation of antibody in the serum; this is consistent with previous studies with anti-CD19 antibodies that revealed that a dose of 15-30 mg was sufficient to coat circulating tumor cells and a dose of at least 1000 mg was required to saturate lymph nodes [23] . The high doses of Rituximab provide long exposure to the antibody since it remains in the serum beyond three months post-treatment. It is possible that antibodies bound to tumor cells could persist even longer than the antibodies detected in serum. The high total doses and the persistence of the antibody in serum contribute to the clinical success of this treatment; the long lasting serum levels may provide a 'maintenance' effect.
The T1/2 of Rituximab was 76.3 hours after the first infusion and 205.8 hours after the fourth infusion. The Rituximab T 1/2 was longer than the T 1/2 found by investigators using other monoclonal antibodies. In these other studies the half-lives ranged from approximately two to 60 hours [7, 24, 25] . Longer half-lives were found in patients being treated with murine anti-idiotype antibodies in situations where there were no circulating level of idiotype protein or no accessible lymphoma cells in the blood or bone marrow [2] . Similarly, longer half-lives were found in patients treated with other chimeric or humanized antibodies such as CAMPATH 1H [22] . The explanations for the long T 1/2 with Rituximab may be a combination of factors including the absence of free circulating CD20 antigen, the minimal number of circulating CD20 positive B cells after the first infusion, and the homology between Rituximab and a human antibody.
The Rituximab T 1/2 increased significantly between the first and fourth infusions. This increase in the T l/2 occurred concomitantly with higher C min and C max serum levels of antibody. The increase in T] /2 is most likely related to elimination of circulating CD20 positive B cells, which serve to clear serum antibody with the initial infusions of Rituximab. In addition, reduction or saturation of accessible involved lymph node sites by Rituximab would also result in decreased antibody clearance and an increased T, /2 which would contribute to increases in the levels of Rituximab in the circulation. Rituximab depletes a subpopulation of B cells but subsequently this subpopulation is repleted by the stem cells. Thus serum level accumulation results from the equilibrium achieved between depletion and repletion of these cells. Despite depletion of circulating normal B lymphocytes, there were no significant drops in mean serum gamma globulin levels and the frequency of infections in general or by encapsulated bacteria was not greater than one might expect in this population [19] .
Other investigators have also found that serum levels of antibody increased as tumor load decreased. For example, Press et al. observed that higher serum levels of the 1F5 murine antibody against CD20 were obtained in patients with little or no circulating B lymphoma cells [7] . Hale et al. reported that detectable levels of the chimeric CAMPATH 1H monoclonal antibody recognizing CDw52 were not seen until after four to six doses when circulating CDw52 lymphocytes had been depleted [26] . Similarly circulating idiotype antigen or idiotype positive lymphoma cells decreased accumulation of serum anti-idiotype antibody levels and also decreased the therapeutic effectiveness of these antibodies [2] .
The median serum level of Rituximab after the fourth and final infusion was between 400 and 500 ug/ml. These levels were higher than levels attained after treatment with most other monoclonal antibodies. For example, peak serum levels ranged from 18-330 ug/ml after treatment with anti-idiotype monoclonal antibodies [2] and between 13 to 190 ug/ml after treatment with 1F5 [7] . A peak level of 35 ug/ml was seen after four injections of anti-Lyml monoclonal antibody at 464 mg per dose [25] and a peak level of 34.5 ug/ml was achieved in one patient after a single 200 mg dose of a chimeric anti-CD4 monoclonal antibody [27] .
We do not clearly understand how the antibody is metabolized. For example, serum levels of Rituximab were detected at three months post-treatment. However given a T 1/2 of 205 hours (8.5 days) and a mean serum concentration of approximately 450 ug/ml post infusion number 4, the measured median Rituximab serum concentration of between 25.4 ug/ml and 5.9 ug/ml for responders and nonresponders at three months posttreatment is higher than expected. This may be due to the 'on/off' or 'steady-state' phenomenon with release of Rituximab from coated but not lysed lymph node or B cells. We found that the serum level of Rituximab was inversely correlated with tumor bulk at baseline as assessed by two different measurements, and also inversely correlated with the numbers of circulating B cells at baseline. This is consistent with the importance of accessible lymphoma in influencing the serum levels of the therapeutic monoclonal antibody. Interestingly we found that the mean serum concentration of Rituximab was significantly lower for patients with IWF Type A. We speculate that this may be related to the higher likelihood of peripheral blood and/or bone marrow involvement with this histology and possibly higher overall tumor/antigen burden; however, this is not measurable as readily as is nodal disease. Another possible explanation for the lower serum levels is that IWF Type A patients have a decreased CD20 antigen density that could result in rapid clearance of the antibody; however, we favor the previous explanation. The association of high serum antibody concentration and response and the association of high serum antibody concentration with lower tumor bulk suggest that higher doses (or more doses) of Rituximab may be necessary to induce responses in some subsets of patients such as those with bulky disease. Nevertheless, responses were seen with Rituximab in 43% of patients with tumors greater than 5 cm and in 35% of patients with tumors greater than 7 cm.
We have thus shown that Rituximab is a novel and effective immunotherapy in patients with low-grade lymphoma. Comprehensive pharmacokinetic data has demonstrated an association between clinical response and accumulation of higher serum levels of the antibody both during and after treatment. Although high serum levels of the antibody may be a surrogate measure for low bulk of disease which itself may be a favorable prognostic factor, we feel that it is more likely that the higher concentrations of Rituximab may actually be mediating more effective tumor regression. Future studies will address whether anti-tumor activity can be enhanced even further by administration of larger total doses of Rituximab.
